Caribou Biosciences
CRBU
88 hedge funds and large institutions have $704M invested in Caribou Biosciences in 2021 Q3 according to their latest regulatory filings, with 88 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
50.13% more ownership
Funds ownership: 0% → 50.13% (+50%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$100M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$81.2M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$72.4M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$60.5M |
| 5 |
Alkeon Capital Management
New York
|
+$30.5M |
Top Sellers
CRBU Hedge Fund Activity: Q3 2021 in Review
88 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Caribou Biosciences (CRBU) for Q3 2021, worth a combined $704M.
Buyers outnumbered sellers: 88 funds opened new CRBU positions and 0 closed out — a net gain of 88 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was PFM Health Sciences, opening a new position worth an estimated $100M.
- 88 institutional investors held Caribou Biosciences (CRBU) as of Q3 2021, up from 0 in Q2 2021.
- Funds reported $704M of Caribou Biosciences stock for Q3 2021.
- 88 funds opened new Caribou Biosciences positions in Q3 2021 and 0 closed out, a net change of +88 holders.
- The largest Caribou Biosciences buyer in Q3 2021 was PFM Health Sciences, an estimated $100M added.
Based on aggregated 13F filings for Q3 2021.